Literature DB >> 10167343

Theoretical issues in cost-effectiveness analysis.

M C Weinstein, W G Manning.   

Abstract

Mesh：

Year:  1997        PMID： 10167343     DOI： 10.1016/s0167-6296(96)00511-5

Source DB:  PubMed          Journal:  J Health Econ        ISSN： 0167-6296            Impact factor:   3.883


× No keyword cloud information.
  9 in total

1.  Willingness to pay. What's in a name?

Authors:  A Gafni
Journal:  Pharmacoeconomics       Date:  1998-11       Impact factor: 4.981

2.  The measurement of contingent valuation for health economics.

Authors:  Ahmed M Bayoumi
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 3.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Building Efficient Crime Prevention Strategies: Considering the Economics of Investing in Human Development.

Authors:  D Max Crowley
Journal:  Criminol Public Policy       Date:  2013-05

5.  A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.

Authors:  R J Milne; S Vander Hoorn; R T Jackson
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

6.  Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate.

Authors:  J P Marissal; B Selke; T Lebrun
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

7.  Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial.

Authors:  M Ekman; N Zethraeus; B Jönsson
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

8.  Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.

Authors:  Michelle Tew; Philip Clarke; Karin Thursky; Kim Dalziel
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

Review 9.  Wickedness or folly? The ethics of NICE's decisions.

Authors:  K Claxton; A J Culyer
Journal:  J Med Ethics       Date:  2006-07       Impact factor: 2.903
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.